Industry must ‘stand hard’ against H.R. 3, Novartis CEO says

There is no time for the biopharmaceutical industry to bask in the glow from its success in developing COVID-19 countermeasures, according to Novartis CEO Vasant Narasimhan. In an interview with BioCentury, he advised the industry to “stand hard in this moment” to persuade Congress against enacting pending drug price-setting legislation that he said could destroy the industry’s ability to innovate. 

BioCentury spoke with Narasimhan as Democratic leadership of the U.S. House of Representatives is pushing to include the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) in a budget bill that incorporates many of the party’s top agenda items. ...